Cancer is the second cause of death worldwide and it was estimated to become the leading in 2060. Cancer treatment is mainly based on chemotherapy, which is associated with a large variety of side effects. The use of natural adjuvants endowed with anticancer properties is considered a good strategy to reduce the chemotherapy dose, thus increasing its tolerability. In our previous work, we proved the anticancer activity of O. crenata leaves acetonic extract (OCLAE) against human breast cancer cell line MCF-7. The Human Foreskin Fibroblasts (HFF-1) cell line was used as the control cell line. The cytotoxic activity of the extract was compared to the standard drug Doxorubicin. MCF-7 cells were treated with increasing concentrations of OCLAE (75-1200mg/mL) for 24h. The cytotoxic effect of the extract was evaluated by MTT and LDH assays. The extract induced a significant reduction of MCF-7 cell viability and a significant increase in LDH release. These effects were correlated to the antioxidant properties of the extract. The obtained results led us to further explore the anticancer properties of O. crenata. In the present study, we evaluated the anticancer activity of O. crenata leaves aqueous extract (OCLAqE) against human colorectal cancer cell lines Caco-2 and HCT-116. Cisplatin, a potent chemotherapeutic agent, was used as the standard drug. The effect of both extract and Cisplatin was also tested on non-cancerous Human Dermal Fibroblast (HDF). Caco-2 and HCT-116 cell lines were exposed to increasing amounts of OCLAqE (10-160mg/mL) or Cisplatin (0.1 to 100 μM) for 24h, 48h, and 72h. The anticancer activity was evaluated by MTT assay. The potential synergistic effect between the two agents was assessed through MTT and Annexin V/ Propidium Iodide assays. The effect of the extract on ROS levels was revealed using 2,7-dichlorodihydrofluorescein diacetate. Finally, by UPLC-Ms/Ms the chemical profile of OCLAqE was obtained. The extract affected Caco-2 and HCT-116 cell viability at all time points. However, it dosedependently reduced Caco-2 cell viability, starting from 40mg/mL. The treatment of HDF with the extract induced a significant reduction of cell viability only at the highest tested concentration (160mg/mL). Co-treatment of extract (80μg/ml) with a subtoxic concentration of cisplatin (1 μM) potentiated the drug effect. The extract was also able to modulate ROS production. Finally, the chemical analysis detected different polyphenolic compounds that could mediate the observed effects. These findings highlighted the anticancer properties of OCLAqE, thus suggesting its potential value as a promising therapeutic adjuvant.
Anticancer activity of Orobanche crenata Forssk. leaves extracts against different human cancer cell lines
D'Angeli F;Genovese C;
2024-01-01
Abstract
Cancer is the second cause of death worldwide and it was estimated to become the leading in 2060. Cancer treatment is mainly based on chemotherapy, which is associated with a large variety of side effects. The use of natural adjuvants endowed with anticancer properties is considered a good strategy to reduce the chemotherapy dose, thus increasing its tolerability. In our previous work, we proved the anticancer activity of O. crenata leaves acetonic extract (OCLAE) against human breast cancer cell line MCF-7. The Human Foreskin Fibroblasts (HFF-1) cell line was used as the control cell line. The cytotoxic activity of the extract was compared to the standard drug Doxorubicin. MCF-7 cells were treated with increasing concentrations of OCLAE (75-1200mg/mL) for 24h. The cytotoxic effect of the extract was evaluated by MTT and LDH assays. The extract induced a significant reduction of MCF-7 cell viability and a significant increase in LDH release. These effects were correlated to the antioxidant properties of the extract. The obtained results led us to further explore the anticancer properties of O. crenata. In the present study, we evaluated the anticancer activity of O. crenata leaves aqueous extract (OCLAqE) against human colorectal cancer cell lines Caco-2 and HCT-116. Cisplatin, a potent chemotherapeutic agent, was used as the standard drug. The effect of both extract and Cisplatin was also tested on non-cancerous Human Dermal Fibroblast (HDF). Caco-2 and HCT-116 cell lines were exposed to increasing amounts of OCLAqE (10-160mg/mL) or Cisplatin (0.1 to 100 μM) for 24h, 48h, and 72h. The anticancer activity was evaluated by MTT assay. The potential synergistic effect between the two agents was assessed through MTT and Annexin V/ Propidium Iodide assays. The effect of the extract on ROS levels was revealed using 2,7-dichlorodihydrofluorescein diacetate. Finally, by UPLC-Ms/Ms the chemical profile of OCLAqE was obtained. The extract affected Caco-2 and HCT-116 cell viability at all time points. However, it dosedependently reduced Caco-2 cell viability, starting from 40mg/mL. The treatment of HDF with the extract induced a significant reduction of cell viability only at the highest tested concentration (160mg/mL). Co-treatment of extract (80μg/ml) with a subtoxic concentration of cisplatin (1 μM) potentiated the drug effect. The extract was also able to modulate ROS production. Finally, the chemical analysis detected different polyphenolic compounds that could mediate the observed effects. These findings highlighted the anticancer properties of OCLAqE, thus suggesting its potential value as a promising therapeutic adjuvant.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
